Stock market – Lonza stocks wanted thanks to advances in Moderna’s Covid-19 vaccine


The impetus comes from news from the US partner Moderna. The Americans want to apply for emergency approval for the Covid-19 vaccine in the USA and Europe in the coming hours. Lonza is contracted to manufacture the vaccines and would benefit from an early launch.

At 1:42 p.m., Lonza names gained 4.5 percent to 576.80 francs. The daily highs are even at 580 francs. In return, the overall market (SMI) is trading 0.4 percent above its closing level on Friday.

As reported from the trading rooms of local banks, the Covid-19 vaccine from Lonza partner Moderna could hit the market a few weeks earlier than originally thought. The company itself announced in a press release that around 20 million vaccine doses could be available in the USA this year. In 2021, between 500 million and a billion batches of the vaccine are expected to be produced and used worldwide.

According to observers, however, it is still unclear how much ultimately the bottom line of each vaccine dose produced remains with Lonza. Nevertheless, the good news is welcomed. The same applies to the statements about the effectiveness of the vaccine.

With a gain of more than 63 percent, Lonza shares top this year’s list of winners from the SMI. The driving force behind the course advances was and is, not least, the hope of commercial success for the Covid-19 vaccine from US partner Moderna.


Source link


Please enter your comment!
Please enter your name here